GLP1R

Chr 6

glucagon like peptide 1 receptor

Also known as: GLP-1, GLP-1-R, GLP-1R

This gene encodes a 7-transmembrane receptor for glucagon-like peptide 1 (GLP-1), which stimulates glucose-dependent insulin secretion. The receptor, located on the cell surface, is internalized upon ligand binding and triggers signaling pathways that regulate insulin release, appetite, gastric emptying, and energy balance. It also has neuroprotective and cardiovascular effects. Polymorphisms in this gene are linked to type 2 diabetes risk, and the receptor is a key drug target for diabetes, obesity, and stroke therapies. [provided by RefSeq, Mar 2026]

ResearchGenerating clinical summary…
12
Active trials
166
Pubs (1 yr)
P/LP submissions
P/LP missense
LOEUF
Multiple*
Mechanism· predicted
Some data sources returned errors (2)

gnomad: Error: gnomAD API error: 502

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

Constraint data not available from gnomAD.

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

GLP1R · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Peripheral Arterial Disease (PAD)Claudication, IntermittentChronic Limb-Threatening Ischemia

Expression of GLP1 Receptor on Peripheral Blood Mononuclear Cells in Advanced Peripheral Artery Disease: Paving the Way for GLP1R Agonists Treatment in Chronic Limb Threatening Ischemia

NOT YET RECRUITING
NCT07340112University Hospital, Strasbourg, FranceStarted 2026-06
Analysis of GLP-1 receptor expression
Pancreatic CancerPDAC - Pancreatic Ductal AdenocarcinomaHyperglycemia

Monitoring and Managing Glucose Levels in People With Pancreatic Cancer

RECRUITING
NCT05132244Phase NABritish Columbia Cancer AgencyStarted 2024-04-16
Endocrinologist-directed target blood glucose level 4-10 mmol/L using data from a continuous glucose monitor (CGM)Standard Care
Obesity & OverweightCardiometabolic Health IndicatorsAddiction

Tirzepatide Impact Assessment Study

RECRUITING
NCT07740291Phase NATexas Tech UniversityStarted 2025-01-02
GLP-1 Receptor Agonist TherapyStructured Lifestyle Intervention
glp1 AgonistGene ExpressionSkin Laxity

Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists

RECRUITING
NCT07224880Cytrellis Biosystems, Inc.Started 2025-10-14
ellacor
Type 1 Diabetes Mellitus

The MICRON Study - A Steno 1 Substudy

RECRUITING
NCT07270172University of AarhusStarted 2025-10-27
Overweight and Obesity

Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment

RECRUITING
NCT06069622Brigham and Women's HospitalStarted 2023-11-01
24-hour ambulatory blood pressureLiberal salt diet
Obesity (Disorder)Metabolic Disorders

Hormonal and Microbiota Modulation After Endoscopic Sleeve Gastroplasty

NOT YET RECRUITING
NCT07576777Phase NAAssistance Publique - Hôpitaux de ParisStarted 2026-05-04
Laparoscopic sleeve gastrectomyEndoscopic sleeve gastroplasty
Diabetic NephropathiesKidney DiseasesRenal Insufficiency, Chronic

Transformative Research in Diabetic Nephropathy 2.0

RECRUITING
NCT07444203University of PennsylvaniaStarted 2025-11-12
Sodium-glucose cotransporter 2 inhibitors (SGLT2i)Renin-angiotensin-aldosterone system blockadeGlucagon-like peptide-1 receptor agonists (GLP 1 RA)
Autosomal Dominant Polycystic KidneyObesity

Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

RECRUITING
NCT06582875Phase PHASE2University of Colorado, DenverStarted 2025-03-06
TirzepatidePlacebo
Chronic Kidney DiseasesMAFLD

Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide.

NOT YET RECRUITING
NCT07391267Phase NAInstitute of Liver and Biliary Sciences, IndiaStarted 2026-02-01
Semaglutide Oral TabletPlaceboStandard medical treatment
Rectal Cancer PatientsObesity &Amp; OverweightLocally Advanced Rectal Cancer (LARC)

Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer

NOT YET RECRUITING
NCT07314528Phase PHASE2St. James's Hospital, IrelandStarted 2026-04
GLP-1 receptor agonistTotal neoadjuvant therapy (TNT)
PreDiabetes

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

RECRUITING
NCT05119179Phase PHASE4The University of Texas Health Science Center, HoustonStarted 2021-11-22
Semaglutide